10BagR, the challenge as always is the following;
- said Donald McCaffrey, President and CEO at Resverlogix. "This exciting program will be added to a growing list of our compassionate use efforts that include post COVID-19 conditions, vascular dementia and chronic kidney disease, in addition to our upcoming core program Phase 3 clinical trial, BETonMACE2."
Over at Zenith Epigenetics they have I think 11 active trials happening yet at RVX with many indications showing promise NOTHING is happening and this is because the management team has no money and they do not know how to raise money.
Once again we have very exciting science happening and nothing can be done about it until there is a new CEO.
Sorry to be so cynical on this beautiful Hump Day but there is a reality which must be addressed by the Board of Directors soon unless, perhaps, there is a mega deal just around the corner...LOL.
GLTA
ToinvÂ
